Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Oct 20 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 4 pages · English

Summary by 6ix AI

The approval is based on the company's New Drug Application for Sitagliptin tablets in various strengths. This milestone reflects Zydus' commitment to providing affordable treatment options for diabetes management. The press release emphasizes the company's dedication to innovative healthcare solutions.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 20, 2023, titled "Zydus receives USFDA approval for ZITUVIOTM to treat adult patients with type 2 diabetes mellitus".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases